The Heartsbreath test determines whether patients with heart transplants are showing signs of rejecting their new heart. It is non-invasive and risk-free. FDA approved the test for clinical use as an adjunct to biopsy.
"We are at the point where it makes sense to interest other companies in licensing this breath test so that it can be sold to hospitals and doctors," said Menssana founder and CEO Michael Phillips, MD. Phillips is a clinical professor of internal medicine at New York Medical College, Valhalla, NY, and a Fort Lee resident. The Enterprise Development Center (EDC) at NJIT, which keeps new technology businesses alive and growing in New Jersey, operates the incubator program.
"One day I hope to see our breath testing equipment, which is relatively small and easy to use, in every physician's office and hospital lab," Phillips added. "Our tests can not only save lives, but they can make medicine less frightening for millions of people," (EDITOR'S NOTE: To interview Phillips either in his lab or by telephone, contact Sheryl Weinstein at 973-596-3436.)
"Doctors have used breath to uncover disease since the time of Hippocrates in Ancient Greece. We've known for more than 2000 years that a diabetic's breath smells fruity, like rotten apples. We now know that it's because of the acetone in their breath. Patients with failing kidneys have breath that smells like urine, and diseases of the liver and the lungs also have distinctive odors. We've taken ancient
'"/>
Contact: Sheryl Weinstein
sheryl.m.weinstein@njit.edu
973-596-3436
New Jersey Institute of Technology
10-Aug-2005